Last Updated : May 29, 2019
Details
Generic Name:
decitabine
Generic Name:
Decitabine
Project Status:
Not filed
Therapeutic Area:
Myelodysplastic Syndromes
Manufacturer:
Pharmascience Inc.
Manufacturer:
Pharmascience Inc.
Brand Name:
Demylocan
Brand Name:
Demylocan
Project Line:
Reimbursement Review
Project Number:
NS0001-000
Submission Type:
Non Submission
Tumour Type:
Other
Indications:
Myelodysplastic Syndromes
Indications:
Myelodysplastic Syndromes
Review Status:
Not Filed
Sponsor:
Recommendation Type:
CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer
Clarification:
CADTH is unable to recommend reimbursement of the relevant product because a submission to CADTH was not filed by the manufacturer.
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Last Updated : May 29, 2019